A phase 1, open label, multicenter trial to assess the safety, tolerability and efficacy of MB-106 in patients with relapsed or refractory CD20+ b-cell NHL or CLL
Ended Project Grant Awarded Last action
- Award ID
- R44CA265616
- Recipient
-
Mustang Bio Inc. UEI GBJLYB9JMDD8
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,996,680
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Funding
-
- $3,997,344.00 Federal
- $999,336.00 Non-federal
- Place of performance
- Worcester, MA 01605, USA
Award details come from USAspending.gov.
Description
- Abstract
- In this application, we propose to optimize the feasibility of mustang BIO's propriety MB-106 and its impact on b- cell non-hodgkin's lymphoma (NHL) and chronic lymphatic lymphoma (CLL) patients and determine an optimal dosage for patients with relapsed or refractory CD20+ b-cell NHL or CLL. While the current courses of molecular targeted therapies have resulted in prolonged remissions, to date there is no curative therapeutic for NHL and CLL cancers. Therefore, an innovative approach is needed for an individualized and specific therapy that can persist past remission dates. Car t cell therapy such as proposed here, is a cellular immunotherapy that uses adoptive t-cells expressing a chimeric antigen receptor specific to targeting tumor-associated b- cell antigens. The methodology proposed is highly individualized, as each product is manufactured individually for each patient. In this direct to phase 2 clinical trial, MB-106 will be tested for efficacy, safety, and determine the optimal dosage for patients. Proposed is an open-label interventional, non-randomized adoptive t-cell immunotherapy study to broaden the understanding the impact of MB-106 in blood, bone marrow, and other sites of disease measured by cytokine levels post infusion. At the conclusion of this project, the recommended dosage of MB-106 for patients will be determined and will be used as the basis for treatment in future clinical trials and ultimate clinical use.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $999,336 | $0 | |
| Amendment | $999,336 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $999,336 | $0 | |
| Original award | $999,336 | $999,336 |
Show all 11
Quick answers
Who received award R44CA265616?
R44CA265616 was awarded to Mustang Bio Inc. by National Cancer Institute (National Institutes of Health) on September 16, 2021.
How much is award R44CA265616 worth?
$4,996,680 has been obligated on R44CA265616: $3,997,344 in federal funding and $999,336 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award